Document ID: chunk:federal_register_of_legislation:F2016L00560:reg:9:p3
Version: federal_register_of_legislation:F2016L00560
Segment Type: reg
Provision Reference: reg 9 (pt 3/6)
Character Range: 10859–14134

receiving total parenteral nutrition or maintenance haemodialysis, at the time of the clinical onset of secondary parkinsonism;
Note: total parenteral nutrition is defined in the Schedule 1 - Dictionary.
            (t)            inhaling, ingesting or having cutaneous contact with cyanide, and having clinical, haematological or biochemical evidence of cyanide intoxication, within the three months before the clinical onset of secondary parkinsonism;
            (u)          having an injection containing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) within the three months before the clinical onset of secondary parkinsonism;
            (v)          using khat (Catha edulis), Ecstasy (3,4-methylenedioxymethamphetamine) or the drug methcathinone (ephedrone) within the three months before the clinical onset of secondary parkinsonism;
            (w)        taking a drug or a drug from a class of drugs from the specified list of drugs, for a continuous period of at least seven days within the three months before the clinical onset of secondary parkinsonism;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
            (x)          having a disorder of calcium metabolism from the specified list of disorders of calcium metabolism at the time of the clinical onset of secondary parkinsonism;
Note: specified list of disorders of calcium metabolism is defined in the Schedule 1 - Dictionary.
            (y)          having cirrhosis of the liver at the time of the clinical onset of secondary parkinsonism;
            (z)          having chronic renal failure at the time of the clinical onset of secondary parkinsonism;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
            (aa)       having a disease from the specified list of autoimmune diseases at the time of the clinical onset of secondary parkinsonism; or
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
            (bb)      having a paraneoplastic encephalomyelitis at the time of the clinical onset of secondary parkinsonism;
(3)          inhaling, ingesting or having cutaneous contact with a pesticide from the specified list of pesticides, for a cumulative period of at least 1 000 hours, within the ten years before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: specified list of pesticides is defined in the Schedule 1 - Dictionary.
(4)          having an episode of acute cholinergic poisoning from exposure to an organophosphorus ester within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: acute cholinergic poisoning and organophosphorus ester are defined in the Schedule 1 - Dictionary.
(5)          having moderate to severe traumatic brain injury within the one year before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(6)          having an intracranial space occupying lesion within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(7)          having hydrocephalus, or draining of hydrocephalus, within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: hydrocephalus is